Clinical Trials

Carcinoma, Non-Small-Cell Lung

NCT06017297 2024-11-12

ESR-22-21719

Biliary Tract Neoplasms

NCT05718297 2024-10-08

BOUNCE

Carcinoma, Non-Small-Cell Lung

NCT05757843 2024-09-19

Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab

Carcinoma, Non-Small-Cell Lung

NCT04944173 2024-09-03

SCION

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm, Residual

NCT05572476 2024-06-05

LURBIMUNE

Small Cell Lung Carcinoma

NCT05209529 2024-02-23

Chemo-free BRCA-targeted Neoadjuvant Strategy

Breast

Triple Negative Breast Neoplasms

NCT05161533 2023-10-18

Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial

Lung Neoplasms

NCT04625699 2023-06-06

Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment

Carcinoma, Non-Small-Cell Lung

NCT03982173 2023-01-26

MATILDA

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05383001 2022-09-27

Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)

Carcinoma, Non-Small-Cell Lung

NCT04001413 2022-07-29

Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients

Head & Neck

Oropharyngeal Neoplasms

NCT04470674 2022-03-03

Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03319316 2022-01-10

SOLUTION

Squamous Non-small Cell Lung Cancer

NCT04262869 2021-10-27

Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03872505 2021-08-25

PANDoRA

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04262375 2020-11-17

DOMINATION

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

NCT04262388 2020-11-17

DOME

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT04231864 2020-10-26

Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer

Head & Neck

Nasopharyngeal Carcinoma

NCT04145193 2020-09-21

Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC

Colonic Neoplasms, Colorectal Neoplasms

NCT03038477 2020-09-14

A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection

Pancreatic Neoplasms

NCT03598816 2020-08-13

PIVOT-RCC

Genitourinary

Carcinoma, Renal Cell

NCT04184518 2020-06-02

CEDUVEAL-M

Dermatologic

Uveal Melanoma, Neoplasm Metastasis

NCT02885727 2019-09-12

Panc-Durval+RT

Pancreatic Neoplasms

NCT03419559 2019-04-16

Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

NCT03241017 2018-04-09

IDA-D

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03004105 2018-03-16

MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

NCT02966587 2018-01-17

Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Microsatellite Instability

NCT03130764 2017-12-06

Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC

Carcinoma, Non-Small-Cell Lung

NCT03150836 2017-10-19

Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer

Genitourinary

Urinary Bladder Neoplasms

NCT02673814 2016-08-01

Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer